Icon clinical trials specialist reports 48% rise in profits

ICON, the Dublin-based clinical trials and medical devices specialist, has again increased its full-year guidance for its current fiscal year, after its second quarter figures comfortably beat market estimates.

The pharmaceutical services company, which is listed on New York’s Nasdaq exchange, yesterday reported a 48.5% year-on- year rise in net revenues to $218.3 million (€137.2m) for the three months to the end of June.

Irish-based analysts had initially forecast net revenue gains for the company of 42% to just over $209m. For the first half of its financial year, Icon has now seen a year-on-year rise in net revenue of 48.2% to $419.6m.